Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지

Cost-Effectiveness Analysis of Glimepiride or Pioglitazone in Combination with Metformin in Type-2 Diabetic Patients

제2형 당뇨병 환자에 대한 메트포르민-글리메피리드 병합요법과 메트포르민-피오글리타존 병합요법의 비용-효과분석

  • Received : 2009.08.31
  • Accepted : 2009.11.23
  • Published : 2009.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

배경: 당뇨병 환자에게 관상동맥심질환은 생존률, 건강 상태 유지 및 삶의 질에 주요한 영향을 미치는 합병증이며 적극적인 당뇨병 치료는 이러한 심혈관 합병증을 예방할 수 있으나 당뇨병의 적극적 치료와 관리에는 많은 비용이 소요된다. 목적: 제2형 당뇨병 환자를 대상으로 메트포르민과 글리메피리드 병합요법과 메트포르민과 피오글리타존 병합요법의 비용-효과성을 비교하고자 하였다. 연구방법: 마르코프 코호트 프로세스(Markov Cohort Process Model) 모형을 이용하여 비용-효과분석을 실시하였다. 연장된 수명 (life years gained, LYG)과 삶의 질(quality)을 보정하여 증가된 QALYs를 주요 효과 지표로 측정하였고, 총비용으로는 직접의료비용과, 환자와 가족의 교통비를 직접비의료비용으로 고려하였고 환자와 가족의 시간비용을 간접비용으로 포함하였다. 연구결과: 비용-효과분석 결과, 메트포르민과 글리메피리드 병합요법의 경우 총 비용은 5,962,288원, 효과는 7.94LYG, 6.43QALY이었다. 반면 메트포르민과 피오글리타존 병합요법은 총 비용 10,982,243원, 효과 8.62LYG, 6.99QALY으로, 점증적 비용-효과비(ICER)는 7,402,663원/LYG과 8,934,546원/QALY 이었다. 결론: 우리 사회의 연장된 수명(LYG)에 따른 지불의사가 700만원 이하인 경우는 메트포르민과 글리메피리드 병합요법이 비용-효과적인 대안이며 700만원 이상인 경우에는 메트포르민과 피오글리타존 병합요법이 비용-효과적인 대안이 될 수 있다.

Keywords

References

  1. Korean Diabetes Association, Health Insurance Review & Assessment Service. Diabetes in Korea. 1st ed. Health Insurance Review & Assessment Service, 2007: 7-73.
  2. Ole-Petter R. Hamnvik, Graham T. McMahon. Glycemic targets for patients with type 2 diabetes mellitus. Mount Sinai Journal of Medicine 2009; 76: 227-33. https://doi.org/10.1002/msj.20117
  3. Molyneaux LM, Cinstantino MI, McGill M, Zilens R, Yue DK. Better glycemic control and risk reduction of diabetic complications in type 2 diabetes: complication with the DCCT. Diabetes Res Clin Pract 1998; 42: 77-83. https://doi.org/10.1016/S0168-8227(98)00095-3
  4. Turnur RC, Neil HAW, Statton IM, Manley SE, Matthews DR, Holman RR. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS23). BMJ 998; 316: 823-8. https://doi.org/10.1136/bmj.316.7134.823
  5. UK Prospective Diabetes Study Group. Intensive bloodglucose control with sulphonylurease or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53. https://doi.org/10.1016/S0140-6736(98)07019-6
  6. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complication in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65. https://doi.org/10.1016/S0140-6736(98)07037-8
  7. UK Prospective Diabetes Study Group. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). Diabetes Care 1999; 22: 1125-36. https://doi.org/10.2337/diacare.22.7.1125
  8. UK Prospective Diabetes Study Group. Tight blood pressure control and risk macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ 1998; 317: 703- 13. https://doi.org/10.1136/bmj.317.7160.703
  9. Gray A, Raikou M, McGuire A, et al. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomized controlled trial (UKPDS 41). BMJ 2000; 320: 1373-78. https://doi.org/10.1136/bmj.320.7246.1373
  10. Clarke P, Gray A, Adler A, et al. Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS 51). Diabetologia 2001; 44: 298-304. https://doi.org/10.1007/s001250051617
  11. Clarke P, Gray A, Holman RR. Estimating utility values for health states of type 2 diabetic patients using the EQ- 5D(UKPDS 62). Med Decis Making 2002; 22: 340-9. https://doi.org/10.1177/027298902400448902
  12. David C. Goff, Jr., et al. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the action to control cardiovascular risk in diabetes (ACCORD) trial. Am J Cardiol. 2007; 99: 4i-20i. https://doi.org/10.1016/S0002-9149(07)00488-2
  13. Cugnet-Anceau C, Bauduceau B. Glycaemic control and cardiovascular morbid-mortality: the contribution of the 2008 studies. 2009; 70: 48-54. https://doi.org/10.1016/j.ando.2008.12.008
  14. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis. JAMA 2002; 287: 2670-81.
  15. Harris MI, Eastman RC, Cowie CC. CHD mortality in diabetics and non-diabetics: NHANES results. Cardiology Rev 2000; 17: 22-8.
  16. Muggeo M. Long-term instability of fasting plasma glucose predicts mortality in elderly NIDDM patients: the Verona Diabetes Study. Diabetologia 1995; 38: 672-9. https://doi.org/10.1007/BF00401838
  17. McGovern PG, Jacobs DR, Shahar E, et al. Trends in acute coronary heart disease mortality, morbidity, and medical care from 1985 through 1997. The Minnesota Heart Survey Circulation 2001; 104: 19-24.
  18. Klein R, Klein BEK, Moss SE, Cruickshanks KJ. The Wisconsin epidemiologic study of diabetic retinopathy XV; The long-term incidence of macular edema. Ophthalmology 1995; 102: 7-16. https://doi.org/10.1016/S0161-6420(95)31052-4
  19. Moss SE, Klein R, Klein BEK. Long-term incidence of lower-extremity amputations in a diabetic population. Arch Fam Med 1996; 5: 391-8. https://doi.org/10.1001/archfami.5.7.391
  20. Wannamthee SG, Shaper AG, Lennon L. Cardiovascular disease incidence and mortality in older men with diabetes and in men coronary heart disease. Heart 2004; 90: 1398-403. https://doi.org/10.1136/hrt.2003.026104
  21. Haffner SM, Letho S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and non-diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34. https://doi.org/10.1056/NEJM199807233390404
  22. Golbourt U, Physical activity, long-term CHD mortality and longevity: a review of studies over the last 30 years. World review of nutrition and dietetics 1997; 82: 229-39.
  23. Verschurn, WMM., Total cholesterol in relation to 25- year CHD and total mortality in seven countries study. Acta cardiol 1994; 49: 316-8.
  24. Vivian EM, Rubinstein GB. Pharmacological management of diabetic nephropathy. Clin Ther 2002; 24: 1741-56. https://doi.org/10.1016/S0149-2918(02)80076-5
  25. Hadden DR. Macrovcular disease and hyperglycaemia:10 year survival analysis in type 2 diabetes mellitus: the Belfast diet study. Diabetic Medicine 1997; 14: 663-72. https://doi.org/10.1002/(SICI)1096-9136(199708)14:8<663::AID-DIA450>3.0.CO;2-Y
  26. Bagust A, Hopkinson PK, Maier W, Currie CJ. An economic model of the long-term health care burden of type II diabetes. Diabetologia 2001; 44: 2140-55. https://doi.org/10.1007/s001250100023
  27. Bagust A, Evans M, Beale S, Home PD, Perry AS, Stewart M. A model of long-term metabolic progression of type 2 diabetes mellitus for evaluating treatment strategies. Pharmacoeconomics 2006; 24(suppl).1: 5-19.
  28. Coyle D, Palmer AJ, Tam R. Economic evaluation of pioglitazone hydrochloride in the management of type 2 diabetes mellitus in Canada. Pharmacoeconomics 2002; 20: 31-42.
  29. Ramsdell JW, Braunatein SN, Stephens JM, Bell CF, Botteman MF, Devine ST. Economic model of first-line drug strategies to achieve recommended glycaemic control in newly diagnosed type 2 diabetes mellitus. Pharmacoeconomics 2003;21:819-37. https://doi.org/10.2165/00019053-200321110-00005
  30. Brown JB, Russell A, Chan W, Pedula K, Aickin M. The global diabetes model: user friendly version 3.0. Diabetes Res Clin Pract 2000; 50: 15-46.
  31. Neeser K, Lubben G, Siebert U, Schramm W. Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from German statutory healthcare perspective. Pharmacoeconomics 2004; 22: 321-41. https://doi.org/10.2165/00019053-200422050-00006
  32. Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM. Diabetes Care 1997; 20: 725-34. https://doi.org/10.2337/diacare.20.5.725
  33. Beale S, Bagust A, Shearer AT, Martin A, Hulme L. Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK. Pharmacoeconomics 2006; 21: 21-34.
  34. Bagust A, Beale S. Modeling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ. 2005; 14: 217-30. https://doi.org/10.1002/hec.910
  35. Veenstra DL, Ramsey SD, Sullivan SD. A guideline for the use of pharmacoeconomic models of diabetes treatment in the US managed-care environment. Pharmacoeconomics 2002; 20: 21-30. https://doi.org/10.2165/00019053-200220001-00003
  36. Homes J. Health-related quality of life in type 2 diabetes. Value in Health 2000; 3: 47-51. https://doi.org/10.1046/j.1524-4733.2000.36028.x
  37. Derosa G, Cicero AFG, Gaddi AV, et al. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by metabolic syndrome: a 12- month, double-blind, randomized clinical trial. Clin Ther 2005; 27: 1383-91. https://doi.org/10.1016/j.clinthera.2005.09.003
  38. Derosa G. Different effect of glimepiride and rosiglitazone on metabolic control type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial. Diabetes, Obesity and Metabolism 2006; 8: 197-205. https://doi.org/10.1111/j.1463-1326.2005.00480.x
  39. Umpierrez G, Issa M, Vlajnic A. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy : results of a randomized clinical trial. Curr Med Res Opin 2006; 22: 751-9. https://doi.org/10.1185/030079906X104786
  40. Derosa G, Angelo AD, Ranonesi PD, et al. Metforminpioglitazone and metformin-rosiglitazone effects on nonconventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. J Clin Pharm Ther 2006; 31: 375-83. https://doi.org/10.1111/j.1365-2710.2006.00756.x
  41. Derosa G. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin. Intern Med J 2007; 37: 79-86. https://doi.org/10.1111/j.1445-5994.2007.01238.x
  42. Matthews DR, Charbonne BH, Hanefeld M, Brunetti P, Schernthaner G. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliglazide to metformin in patients with type 2 diabetes: a randomized, comparative study, Diabetes Metab Res Rev 2005; 21: 167-74. https://doi.org/10.1002/dmrr.478
  43. Derosa G, Gaddi AV, Piccinni MN, et al. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial. Diabetes Obes Metab 2006; 8: 197-205. https://doi.org/10.1111/j.1463-1326.2005.00480.x
  44. Stevens RJ, Kothari V, Adler AI, Stratton IM et al. The UKPDS risk engine : a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci 2001; 101: 671-9. https://doi.org/10.1042/CS20000335
  45. Anderson KM, Odell PM, Wilson PWF, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1990; 121: 293-8.
  46. National Health Insurance Corporation. The healthinsurance annual statistical report, 2008
  47. National Health Insurance Corporation. The co-payment realities survey data in the patients with national health insurance, 2006 and 2007
  48. Health Insurance Review Agency. Allowance-item pharmaceutical-price file and weighted average price, 2008
  49. Ministry Institute for Health Welfare and Family Affairs, Health Insurance Review Agency. The data of national health insurance care-benefit cost, 2008
  50. Korea Institute for Health and Social Affairs. National Health and Nutrition Survey, 2001 and 2005
  51. Korea Institute for Health and Social Affairs. National Health Realities Survey data, 2000
  52. Labor Statistics of Korea. Monthly Labor Statistics, 2008